Skip to Main Content

2019 Novel Coronavirus/COVID-19

Guide to the 2019 Novel Coronavirus/COVID-19 outbreak. This guide is dynamic, and resources will be added as they become available.

About

This guide is dynamic and will be updated as new resources become available. It is intended to serve those interested in the illness caused by the novel coronavirus, CoViD-19, or SARS-CoV-2.

COVID-19 MULTILINGUAL RESOURCE HUB

Research

  • Current Scenario in Associating Clinical COVID-19 Biomarkers for Developing Surveillance PlatformsThis link opens in a new windowJan 14, 2025

    Curr Med Chem. 2025 Jan 9. doi: 10.2174/0109298673331044241031100627. Online ahead of print.

    ABSTRACT

    The novel coronavirus that caused the epidemic and pandemic resulting in the acute respiratory illness known as coronavirus disease 2019 (COVID-19) has plagued the world. This is unlike other coronavirus outbreaks that have occurred in the past, such as Middle East respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS). COVID-19 has spread more quickly and posed special challenges due to the lack of appropriate treatments and vaccines. Real-time polymerase chain reaction (RTPCR) and rapid antibody tests (surveillance tests) are the two most used tests (confirmation tests). However, the latter takes hours to complete, and the former may produce false positives. Scientists have invested significant effort to create a COVID-19 diagnostic system that is both highly sensitive and reasonably priced. Early detection of COVID-19 is a major area of focus for sensing devices based on nanomaterials. This overview enhanced insights into potential coronavirus biomarkers and, compared to earlier studies, introduced new avenues. Further, it covers the development of COVID-19 diagnostic systems from an analytical point of view, including clinical markers and their subsequent applications with biosensors.

    PMID:39806951 | DOI:10.2174/0109298673331044241031100627

  • Food needs and health behaviors in the COVID-19 situation: a case study of quarantined communities in densely populated areas of Bangkok, ThailandThis link opens in a new windowJan 13, 2025

    J Health Popul Nutr. 2025 Jan 13;44(1):7. doi: 10.1186/s41043-024-00724-y.

    ABSTRACT

    BACKGROUND: The Thai government's initial response to the novel coronavirus disease 2019 (COVID-19) led to confusion and food insecurity in quarantined low-income communities. Although free food programs were initiated, no official assessment of their impact exists. The objective of this study was to evaluate the effectiveness of these food programs by surveying the food requirements, food needs, and health behaviors of quarantined, densely populated communities in Bangkok.

    METHODS: A cross-sectional descriptive study was conducted with 410 urban dwellers from quarantined communities who received free food assistance. Data were collected via a questionnaire on food requirements, food hygiene, food needs, and health behaviors during the COVID-19 epidemic. The data were analyzed in terms of frequency, percentage, mean, and standard deviation. The associations between demographic characteristics, food needs, and health behaviors were analyzed using logistic regression.

    RESULTS: The participants demanded dried/canned food (54.9%) and three meals per day (64.9%), while the majority of the food provided consisted of rice and side dishes (96.2%) that were clean and qualified. In consideration of food needs, a high level of demand was observed in the first three levels: enough food, acceptable food, and reliability. Overall, dietary health behaviors were good. Logistic regression analysis revealed that being elderly (AOR = 3.67, 95% CI = 1.63-8.27) and having a moderate to high income level (AOR = 3.93, 95% CI = 2.23-6.94) were positively correlated with food needs. Similarly, good health behaviors were positively correlated with being female (AOR = 1.74, 95% CI = 1.12-2.69), being elderly (AOR = 3.73, 95% CI = 1.72-8.08), and having a moderate to high income level (AOR = 3.76, 95% CI = 2.38-5.93).

    CONCLUSIONS: Preparing for future crises requires the consideration of demographic factors that influence food needs, personal choices, and dietary health behaviors. Future food assistance programs should focus on the provision of nonperishable and long-lasting food, which will ensure the consistent availability of three meals per day.

    PMID:39806508 | PMC:PMC11731402 | DOI:10.1186/s41043-024-00724-y

  • In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibitionThis link opens in a new windowJan 12, 2025

    J Mol Graph Model. 2025 Jan 7;136:108939. doi: 10.1016/j.jmgm.2024.108939. Online ahead of print.

    ABSTRACT

    The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well. A growing list of drugs are being suggested by various in silico, in vitro and ex vivo models, however currently only two treatment options are widely used: the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir, and the main protease inhibitor nirmatrelvir in combination with ritonavir. Computational drug development tools and in silico studies involving molecular docking, molecular dynamics, entropy calculations and pharmacokinetics can be useful to identify new targets to treat COVID-19 and PASC, as shown in this work and our recent paper that identified alendronate as a promising candidate. In this study, we have investigated all bisphosphonates (BPs) on the ChEMBL database which can bind competitively to nidovirus RdRp-associated nucleotidyl (NiRAN) transferase domain, and systematically down selected seven candidates (CHEMBL608526, CHEMBL196676, CHEMBL164344, CHEMBL4291724, CHEMBL4569308, CHEMBL387132, CHEMBL98211), two of which closely resemble the approved drugs minodronate and zoledronate. This work and our recent paper together provide an in silico mechanistic explanation for alendronate and zoledronate users having dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations, and indicate that similar observational studies in Japan with minodronate could be valuable.

    PMID:39799876 | DOI:10.1016/j.jmgm.2024.108939

  • Acute gastrointestinal and post-acute COVID-19 gastrointestinal syndrome assessment on the Gastrointestinal Symptom Rating Scale scoring system: A questionnaire-based surveyThis link opens in a new windowJan 10, 2025

    J Family Med Prim Care. 2024 Dec;13(12):5787-5798. doi: 10.4103/jfmpc.jfmpc_707_24. Epub 2024 Dec 9.

    ABSTRACT

    BACKGROUND: Post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) is the persistence of sequel of acute SARS-COV-2 infection. Persistent/acquired gastrointestinal symptoms (GI-PACS) include loss of appetite, nausea, weight loss, abdominal pain, heartburn, dysphagia, altered bowel motility, dyspepsia, and irritable bowel syndrome. The study aimed to assess the short- and long-term GI-PACS syndrome on the GSRS scale.

    METHODS: A cross-sectional, retrospective record analysis and telephonic questionnaire-based survey were conducted at a tertiary referral center in northern India. The data incorporated patients treated from April 2021 to March 2023. Exclusion criteria were neurological disorders, dementia, inability to understand Hindi/English languages, and psychiatric problems. All patients who met the inclusion criteria were telephonically called from November 2023 to January 2024.

    RESULTS: The study population was 350 recovered patients from SARS-COVID-19 illness. Forty-three responses were removed during data cleaning and removal of duplication. The data analysis of 307 participants (ICU admissions=92, non-ICU admissions=123, and outdoor treatment =92) was done. The proportion of patients not having any GI symptoms, having at least one GI symptom, and having more than one GI symptom before SARS-COV-2 illness was 3%(3/307), 4.9% (15/307), and 3.6% (11/307), respectively. The four major GI symptoms analyzed in the study were vomiting, pain in the abdomen, diarrhea, and constipation. Overall, 13% (40/307) of the study population did not have any major GI symptoms before SARS-COV-2 diseases. During acute SARS-COV-2 illness, 86.97% (267/307) of patients develop new GI symptoms. Post SARS-COV-2 illness, the overall mean GSRS score for 15 items was 2.14 ± 0.829. The acquired GI-PACS was abdominal pain syndrome (mean score 2.5190 ± SD 0.86650), constipation syndrome (mean score 2.3844 ± 0.83840), reflux syndrome (mean score 2.2866 ± 1.31889), indigestion syndrome (mean score 1.8591 ± 0.93076), and diarrhea syndrome (mean score 1.8122 ± 0.90899). Overall, fever (95.1%, P = 0.007), anosmia (45.0%, P = 0.042), cough (80.1%, P = 0.032), and hospitalization (30.0%, P = 0.003) had a more significant association with one of the major four GI symptoms during the acute phase of SARS-COV-2 illness. Home-isolated patients having loss of appetite (95.4%, P = 0.0001) had a significant association with one of the major four GI symptoms during the acute phase of SARS-COV-2 illness. Hospitalized patients having fever (80.7%, P = 0.031), breathlessness (83.8%, P = 0.003), loss of smell (97.0%, P = 0.001), and cough (82.7%, P = 0.048) had a more significant association with one of the major four GI symptoms during the acute SARS-COV-2 illness. Abdominal pain, reflux, and constipation were considered severe GI symptoms (symptom GSRS score greater than total mean GSRS score). Diarrhea and indigestion were considered mild symptoms (symptom GSRS score was less than the total mean GSRS score). The GI symptoms during acute SARS-COV-2 illness recovered in 66.1% (203/307) patients within 3 months. The respondents taking medicines for more than 1 year following SARS-COV-2 illness were 19.2%. 12.0% (37/307) of respondents suffered from persistent GI symptoms on a mean follow-up of 20.1 ± 0.82 months.

    CONCLUSION: Long-term COVID-19 syndrome frequently manifested as GI symptoms, whereas most symptoms subsided with time.

    PMID:39790770 | PMC:PMC11709014 | DOI:10.4103/jfmpc.jfmpc_707_24

  • Risk Factors for Falls in Community-Dwelling Older Adults During the Novel Coronavirus Pandemic in Japan: A Prospective Cohort StudyThis link opens in a new windowJan 8, 2025

    Int J Environ Res Public Health. 2024 Nov 30;21(12):1603. doi: 10.3390/ijerph21121603.

    ABSTRACT

    This study aimed to test the hypothesis that knowledge derived from indirect assessments can be used to identify fall risk factors during a period of social distancing. A baseline survey of 1953 community-dwelling older adults was conducted in May 2020, with a follow-up survey performed in May 2023 to assess the situation 3 years later. In total, 339 individuals were followed from baseline to follow-up. Baseline age, sex, Questionnaire for Change of Life, Frailty Screening Index, and Questionnaire for Medical Checkup of Old-Old (QMCOO) scores and subscales were used to determine fall predictors. In addition, history of falls in the past year was assessed at follow-up (outcome). The participants were categorized into fall (n = 78) and non-fall (n = 261) groups. Using binary logistic regression analysis, items that showed significant differences in a between-group comparison were analyzed, and age and history of falls, which were sub-items of the QMCOO, were identified as predictors of falls. Although special assessments may be required during periods of social distancing, we believe that it is important for these assessments to continue being performed as they are performed during normal times.

    PMID:39767444 | PMC:PMC11675169 | DOI:10.3390/ijerph21121603